Compare PED & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PED | NXTC |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | United States |
| Employees | 14 | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.5M | 46.6M |
| IPO Year | N/A | 2019 |
| Metric | PED | NXTC |
|---|---|---|
| Price | $0.56 | $13.27 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $1.50 | ★ $23.00 |
| AVG Volume (30 Days) | ★ 148.8K | 38.8K |
| Earning Date | 11-17-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 156.43 | N/A |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $33,244,999.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $305.89 | N/A |
| P/E Ratio | $5.33 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.43 | $2.69 |
| 52 Week High | $1.00 | $15.74 |
| Indicator | PED | NXTC |
|---|---|---|
| Relative Strength Index (RSI) | 51.74 | 56.64 |
| Support Level | $0.55 | $12.99 |
| Resistance Level | $0.60 | $14.65 |
| Average True Range (ATR) | 0.03 | 1.00 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 57.90 | 64.24 |
PEDEVCO Corp is an oil and gas company focused on oil and natural gas development, exploration, and production. The company focuses on legacy properties where there is a long production history, well-defined geology and existing infrastructure that can be leveraged when applying modern field management technologies. The current properties of the company are located in the San Andres formation of the Permian Basin, situated in West Texas and eastern New Mexico (the Permian Basin), and in the Denver-Julesberg Basin (D-J Basin) in Colorado and Wyoming.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.